INICIO

Continuation of the Revista Mexicana de Cardiología

  • Home
  • Instructions for authors
    • Instructions for authors
    • Regulations for the publication of supplements
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • About Us
    • About the Journal            
    • Publisher Policies
    • Previous Titles
    • Editorial Management
  • Contact





2022, Supplement 3

Cardiovasc Metab Sci 2022; 33 (S3)

Impact of alternative therapies in the treatment of resistant systemic arterial hypertension

Díaz-y-Díaz, Enrique; Parcero-Valdés, Juan José

ABSTRACT

Resistant arterial hypertension has been defined as a condition where a patient is being treated with an antihypertensive regimen with ≥ 4 drugs or ≥ 3 drugs that include a diuretic and still has blood pressure figures ≥ 140/90 mmHg. Given that the prevalence of resistant arterial hypertension is high, clinicians should be aware of its potential risk of not handling this condition. This review aims to discuss contributors and clinical recommendations to help clinicians better understand and treat resistant arterial hypertension within all care settings. We also demonstrate data from randomized placebo-controlled trials and conclude that renal denervation significantly reduces ambulatory and office blood pressure. Moreover, it was similar between patients on and off background antihypertensive medications. Furthermore, a novel therapy named baroreceptor stimulation therapy has shown promising data in both experimental and clinical experiments to handle resistant arterial hypertension. Both approaches may be highly relevant in patients who are intolerant to medications.
  FULL TEXT PDF  

Keywords

Resistant arterial hypertension renal denervation baroreceptor stimulation therapy




  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5
  • Coronary artery to right pulmonary artery fistula in an adolescent
    2025, Vol.36, Núm. 1
  • Observational Registry for Cardiac Ablation in Atrial Fibrillation in Mexico...
    2025, Vol.36, Núm. 1
  • Statement from the Presidency of ANCAM and its Editorial Committee
    2025, Vol.36, Núm. 1
  • The MACARENHA connection: a holistic approach to understand and fight the...
    2025, Vol.36, Núm. 1
  • Metformin in the management of non-alcoholic fatty liver disease: current...
    2025, Vol.36, Núm. 1
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3

Cardiovascular and Metabolic Science Vol. 33, Num. S3, Julio-Septiembre 2022. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 https://www.cardiovascularandmetabolicscience.org.mx/ ancam@ancam.org.mx https://www.medigraphic.com/cms/ E-mail addresses: revmexcardiol@gmail.com Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-061316491900-203. ISSN: 2683-2828 versión impresa y 2954-3835 versión electrónica. Ambos otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 04 de abril de 2024.

 

2025     |     https://www.cardiovascularandmetabolicscience.org.mx/